{
    "medicine_id": "5064dec2c4cf0f64e646d9988e623cf71a54eee8",
    "platform_id": "DB04942",
    "metadata": {
        "name": "Fulyzaq 125 mg 1 Tablet coated",
        "composition": "125 mg 1 Tamibarotene",
        "clinical_particulars": {
            "therapeutic_indications": "Investigated for use treatment in leukemia unspecified",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Tamibarotene is a new synthetic retinoid drug recently approved for relapsed or refractory acute promyelocytic leukemia APL in Japan It is a specific agonist for retinoic acid receptor alpha beta Compared to all trans retinoic acid ATRA a natural retinoid indicated for a first line treatment of APL tamibarotene is chemically more stable and several times more potent as an inducer of differentiation in promyelocytic leukemia cells In contrast to ATRA whose plasma concentration declines considerably during daily administration tamibarotene sustains plasma level probably due to a lower affinity for cellular retinoic acid binding protein Furthermore adverse side effects were milder than those of ATRA in clinical trials",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}